<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="(http://creativecommons.org/licenses/by/4.0/). Abstract Influenza A virus, one of the major human" exact="respiratory" post="pathogens, is responsible for annual seasonal endemics and unpredictable"/>
 <result pre="respiratory pathogens, is responsible for annual seasonal endemics and unpredictable" exact="periodic" post="pandemics. Despite the clinical availability of vaccines and antivirals,"/>
 <result pre="was effective against multiple isolates of subtype H1N1, but had" exact="limited" post="activity against subtype H3N2, depending on the strain. By"/>
 <result pre="mouse-adapted influenza A virus (H1N1) with nylidrin completely blocked intranasal" exact="viral infection." post="The present study suggests that nylidrin could provide a"/>
 <result pre="Influenza A, belonging to the family Orthomyxoviridae, causes contagious human" exact="respiratory" post="diseases in pandemics and seasonal or zoonotic epidemics. Its"/>
 <result pre="encapsidated with nucleoprotein (NP) through interactions with subunits of the" exact="viral" post="polymerase (polymerase basic protein 1 [PB1], PB2, and polymerase"/>
 <result pre="1 [PB1], PB2, and polymerase acidic protein [PA]) to generate" exact="viral" post="ribonucleoproteins (vRNPs) [1,2]. The viral lipid bilayer envelope bears"/>
 <result pre="acidic protein [PA]) to generate viral ribonucleoproteins (vRNPs) [1,2]. The" exact="viral" post="lipid bilayer envelope bears spikes consisting of major glycoproteins,"/>
 <result pre="neuraminidase (NA), which determine the serologic and antigenic properties of" exact="viral" post="strains, along with a relatively small population of matrix"/>
 <result pre="different vRNPs arranged in the &quot;1 + 7�? pattern [3]." exact="Viral" post="infectivity depends on the function of homotrimeric HA at"/>
 <result pre="function of homotrimeric HA at the initial step of the" exact="viral" post="life cycle, making this surface protein attractive as an"/>
 <result pre="or α-2,6-linked sialic acid receptors on host cells prior to" exact="viral" post="internalization into the endosome [4,5]. Binding of the virus"/>
 <result pre="M2 proton channel opens to facilitate proton transport into the" exact="viral" post="interior, causing vRNPs to dissociate from the inner M1"/>
 <result pre="mediated by nuclear localization signals (NLSs) within NP [8], where" exact="viral" post="RNA replication and transcription occurs. There are three classes"/>
 <result pre="acids attached to HA during the very late stage of" exact="infection" post="and thus interfere with the release of progeny viruses"/>
 <result pre="from host mRNAs during the &quot;cap-snatching�? process, enabling initiation of" exact="viral" post="mRNA synthesis. Despite the high potency of these drugs"/>
 <result pre="health concern, and such mutations have arisen even in the" exact="absence of" post="drug pressure [11]. The majority of currently circulating H1N1"/>
 <result pre="the 2009 pandemic H1N1 and seasonal H3N2 strains confers reduced" exact="susceptibility to" post="baloxavir marboxil [15]. This widespread drug resistance highlights the"/>
 <result pre="Accordingly, preincubation of influenza virus with nylidrin completely blocked intranasal" exact="infection" post="of mice. Thus, nylidrin represents a new class of"/>
 <result pre="and Methods 2.1. Cells and Viruses Madin–Darby canine kidney (MDCK)," exact="African" post="green monkey kidney (Vero) E6, and A549 cells purchased"/>
 <result pre="green monkey kidney (Vero) E6, and A549 cells purchased from" exact="American" post="Type Culture Collection (ATCC, Manassas, VA, USA) were cultured"/>
 <result pre="(H3N2), and B/Brisbane/60/2008 were provided by the Korea Centers for" exact="Disease" post="Control and Prevention (KCDC, Chungcheongbuk-do, Republic of Korea) [19]."/>
 <result pre="(KCDC, Chungcheongbuk-do, Republic of Korea) [19]. Viruses were amplified by" exact="infection" post="of 10-day-old embryonated chicken eggs or MDCK cells in"/>
 <result pre="min, and aliquots were stored at −70 °C before use." exact="Viral" post="titers were determined by plaque assay. Mouse-adapted PR8 virus"/>
 <result pre="from Sigma-Aldrich. The NA inhibitor oseltamivir carboxylate (OSV-C; ≥98%) was" exact="acquired" post="from United States Biological (Swampscott, MA, USA). Cell-based antiviral"/>
 <result pre="or infected with individual influenza strains at a multiplicity of" exact="infection" post="(MOI) of 0.001 to 0.005 for 1 h at"/>
 <result pre="included the four compounds’ inactive compounds. 2.4. Immunoassays To detect" exact="viral" post="proteins, western blot analysis was performed as described previously"/>
 <result pre="35 °C in the presence of nylidrin, OSV-C, or RBV." exact="Viral" post="proteins NP, HA, and M1 were detected by immunoblotting"/>
 <result pre="(cat no. sc-57881; Santa Cruz Biotechnology, Dallas, TX, USA), respectively." exact="Secondary" post="antibodies were horseradish peroxidase (HRP)-conjugated goat anti-mouse or anti-rabbit"/>
 <result pre="were horseradish peroxidase (HRP)-conjugated goat anti-mouse or anti-rabbit IgG (Thermo" exact="Fisher" post="Scientific, Waltham, MA, USA). Cellular β-actin was used as"/>
 <result pre="at 4 °C for 1 h in the presence or" exact="absence of" post="nylidrin. After washing with PBS to remove chemicals and"/>
 <result pre="gallate (EGCG; Sigma-Aldrich) was used as a control for blocking" exact="viral" post="entry. Subsequently, all samples were washed with PBS at"/>
 <result pre="for 5 h at 37 °C in the presence or" exact="absence of" post="nylidrin. After fixation and permeabilization, viral NP was visualized"/>
 <result pre="the presence or absence of nylidrin. After fixation and permeabilization," exact="viral" post="NP was visualized using anti-NP antibody (cat no. sc-80481;"/>
 <result pre="software (Carl Zeiss, Thornwood, NY, USA). For investigating colocalization of" exact="viral" post="NP with cellular Rab5 or Rab7, A549 cells were"/>
 <result pre="and then at 37 °C for an additional 4 h." exact="Viral" post="NP protein was probed using the same primary antibody"/>
 <result pre="4 h. Viral NP protein was probed using the same" exact="primary" post="antibody above-mentioned, but with Alexa Fluor 633-conjugated secondary antibody"/>
 <result pre="the same primary antibody above-mentioned, but with Alexa Fluor 633-conjugated" exact="secondary" post="antibody (Invitrogen). 2.7. Polykaryon Assay Syncytia formation caused by"/>
 <result pre="antibody (Invitrogen). 2.7. Polykaryon Assay Syncytia formation caused by influenza" exact="infection" post="was evaluated as described previously [16,22]. Vero E6 cells"/>
 <result pre="Sino Biological), respectively, followed by incubation with HRP-conjugated goat anti-rabbit" exact="secondary" post="antibody as described above. 2.9. In Vivo Study Female"/>
 <result pre="anti-rabbit secondary antibody as described above. 2.9. In Vivo Study" exact="Female" post="BALB/c mice (6–7 weeks old; Orient Bio Inc., Gyeonggi-do,"/>
 <result pre="Mice were intranasally challenged with maPR8 in the presence or" exact="absence of" post="nylidrin at a dose of 10 mg/kg in a"/>
 <result pre="of nylidrin at a dose of 10 mg/kg in a" exact="total" post="volume of 50 μL. In another control group, oseltamivir"/>
 <result pre="were considered to represent statistical significance. 3. Results 3.1. Anti-Influenza" exact="Viral" post="Activity of Nylidrin and Its Analogues In a screen"/>
 <result pre="with influenza A, but conferred no benefit in CPE-reduction following" exact="infection" post="with an influenza B strain (Lee). To verify this"/>
 <result pre="ritodrine, fenoterol, and bambuterol had no antiviral activity against any" exact="viral" post="strains. In further experiments, we tested the inhibitory compounds,"/>
 <result pre="against A/H1N1 strains, but their efficacy varied among the H3N2" exact="viral" post="strains, and none had antiviral activity in influenza B-infected"/>
 <result pre="labetalol and eliprodil, had little effect against any of these" exact="viral" post="strains, except for A/Brisbane/59/2007 (H1N1), which was partially sensitive"/>
 <result pre="and its analogues, ifenprodil and clenbuterol, can reliably inhibit the" exact="infection" post="of H1N1 strains of the influenza A virus at"/>
 <result pre="sites of the phenyl aminoethanol derivatives is critical for anti-influenza" exact="viral" post="activity in cells. 3.3. Abnormal Accumulation of Nucleoprotein (NP)"/>
 <result pre="it was necessary to determine whether nylidrin could inhibit influenza" exact="viral infection" post="by monitoring viral proteins or plaque reduction directly. We"/>
 <result pre="was necessary to determine whether nylidrin could inhibit influenza viral" exact="infection" post="by monitoring viral proteins or plaque reduction directly. We"/>
 <result pre="determine whether nylidrin could inhibit influenza viral infection by monitoring" exact="viral" post="proteins or plaque reduction directly. We treated PR8-infected MDCK"/>
 <result pre="lysates revealed a dose-dependent decrease in the levels of three" exact="viral" post="proteins, NP, HA, and M1, consistently (Figure 2A). Notably,"/>
 <result pre="nylidrin has antiviral activity in human lung cells, and not" exact="limited" post="in a canine kidney-derived cell line (Supplementary Figure S2)."/>
 <result pre="S2). Culture supernatants also exhibited a significant reduction in the" exact="viral" post="plaque number in the presence of nylidrin (Figure 2B)."/>
 <result pre="(Figure 2B). These results demonstrate that nylidrin is an anti-influenza" exact="viral" post="compound that downregulates viral protein expression and the production"/>
 <result pre="demonstrate that nylidrin is an anti-influenza viral compound that downregulates" exact="viral" post="protein expression and the production of infectious progeny virus."/>
 <result pre="compound that downregulates viral protein expression and the production of" exact="infectious" post="progeny virus. To further investigate which step in the"/>
 <result pre="during adsorption or at various time points p.i. over a" exact="total" post="time of 5 h, in which EGCG was used"/>
 <result pre="EGCG was used as a control for the blocking of" exact="viral" post="entry. This time-of-addition experiment revealed that nylidrin affected influenza"/>
 <result pre="in an incubation period-dependent manner (Figure 2C). Immunofluorescence imaging of" exact="viral" post="NP at 5 h p.i. confirmed that nylidrin prevents"/>
 <result pre="hypothesized that the compound could target one of the three" exact="viral" post="protein functions during the virus entry step, (1) M2"/>
 <result pre="when NP had completely migrated to the nucleus in the" exact="absence of" post="nylidrin (Figure 3). This result suggested that nylidrin could"/>
 <result pre="HA2 (Figure 4A). In quantitative terms, 80.5% and 77.8% of" exact="viral" post="HA2-mediated polykaryon formation was inhibited by 100 μM nylidrin"/>
 <result pre="nylidrin, as an HA2-mediated fusion inhibitor, could protect mice from" exact="viral infection." post="To test its ability, we intranasally infected immunocompetent BALB/c"/>
 <result pre="that nylidrin not only mitigated body weight loss induced by" exact="viral infection" post="(Figure 5A), but also prevented mortality: complete survival (100%)"/>
 <result pre="nylidrin not only mitigated body weight loss induced by viral" exact="infection" post="(Figure 5A), but also prevented mortality: complete survival (100%)"/>
 <result pre="induced by viral infection (Figure 5A), but also prevented mortality:" exact="complete" post="survival (100%) was comparable to that in the OSV-P-treated"/>
 <result pre="Taken together, these findings suggest that nylidrin protects mice from" exact="viral infection" post="in vivo by directly targeting the HA2 function of"/>
 <result pre="together, these findings suggest that nylidrin protects mice from viral" exact="infection" post="in vivo by directly targeting the HA2 function of"/>
 <result pre="a G protein-coupled receptor (GPCR) and primarily expressed on smooth" exact="muscle" post="cells surrounding the bronchioles. ADRB2 exists in equilibrium between"/>
 <result pre="protein-dependent manner [26]. Subsequent sequestration of intracellular Ca2+ leads to" exact="muscle" post="relaxation [27]. Related to the roles of adrenergic receptors"/>
 <result pre="relaxation [27]. Related to the roles of adrenergic receptors on" exact="viral infection," post="it has been suggested that ADRB2 agonists could downregulate"/>
 <result pre="downregulate the innate immune response and reduce host resistance to" exact="viral infection" post="in a murine cytomegalovirus infection model [28]. Another study"/>
 <result pre="the innate immune response and reduce host resistance to viral" exact="infection" post="in a murine cytomegalovirus infection model [28]. Another study"/>
 <result pre="and reduce host resistance to viral infection in a murine" exact="cytomegalovirus infection" post="model [28]. Another study reported that clonidine, an agonist"/>
 <result pre="reduce host resistance to viral infection in a murine cytomegalovirus" exact="infection" post="model [28]. Another study reported that clonidine, an agonist"/>
 <result pre="�?�2 adrenergic receptor (ARDA2), inhibited various influenza strains at the" exact="viral" post="assembly step [29]. As a counterplayer of ADRB2, ARDA2,"/>
 <result pre="degrees of efficacy. However, not all ADRB2 agonists suppressed the" exact="virus infection" post="(e.g., ritodrine, fenoterol, and bambuterol) were inactive. This inspired"/>
 <result pre="of efficacy. However, not all ADRB2 agonists suppressed the virus" exact="infection" post="(e.g., ritodrine, fenoterol, and bambuterol) were inactive. This inspired"/>
 <result pre="small molecules [22,33,34], tend to exhibit antiviral potency in a" exact="viral" post="subtype- or HA group-dependent manner; group I consists of"/>
 <result pre="to be stressed is that nylidrin completely blocked intranasal influenza" exact="infections" post="of mice when it was preincubated with the virus"/>
 <result pre="virus (Figure 5). Even though the OSV-P–treated group showed a" exact="complete" post="therapeutic effect, it led to transient decreases in body"/>
 <result pre="OSV-P–treated group showed a complete therapeutic effect, it led to" exact="transient" post="decreases in body weight after virus challenge. Meanwhile, the"/>
 <result pre="absorption is not sufficient for oral administration to treat influenza" exact="virus infection." post="Future studies could also focus on chemical modifications that"/>
 <result pre="on chemical modifications that would render a broader range of" exact="viral" post="strains sensitive to nylidrin derivatives as well as improve"/>
 <result pre="of nylidrin and its analogues, Figure S2: Reduction of a" exact="viral" post="protein, nucleoprotein (NP) by nylidrin in human lung epithelial"/>
 <result pre="a viral protein, nucleoprotein (NP) by nylidrin in human lung" exact="epithelial" post="cells, Figure S3: No effect of nylidin on the"/>
 <result pre="effect of nylidin on the proton channel activity of influenza" exact="viral" post="M2, Figure S4: Increase of mean survival time of"/>
 <result pre="virion ribonucleoproteinsScience20123381634163710.1126/science.122817223180776 2.PflugA.GuilligayD.ReichS.CusackS.Structure of influenza A polymerase bound to the" exact="viral" post="RNA promoterNature201451635536010.1038/nature1400825409142 3.NakatsuS.SagaraH.Sakai-TagawaY.SugayaN.NodaT.KawaokaY.Complete and Incomplete Genome Packaging of Influenza"/>
 <result pre="A polymerase bound to the viral RNA promoterNature201451635536010.1038/nature1400825409142 3.NakatsuS.SagaraH.Sakai-TagawaY.SugayaN.NodaT.KawaokaY.Complete and" exact="Incomplete" post="Genome Packaging of Influenza A and B VirusesmBio2016710.1128/mBio.01248-1627601575 4.WeisW.BrownJ.H.CusackS.PaulsonJ.C.SkehelJ.J.WileyD.C.Structure"/>
 <result pre="pdm09 and A(H3N2) StrainsJ. Infect. Dis.2020221637010.1093/infdis/jiz41831419295 16.JangY.ShinJ.S.YoonY.S.GoY.Y.LeeH.W.KwonO.S.ParkS.ParkM.S.KimM.Salinomycin Inhibits Influenza Virus" exact="Infection" post="by Disrupting Endosomal Acidification and Viral Matrix Protein 2"/>
 <result pre="16.JangY.ShinJ.S.YoonY.S.GoY.Y.LeeH.W.KwonO.S.ParkS.ParkM.S.KimM.Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and" exact="Viral" post="Matrix Protein 2 FunctionJ. Virol.201892e01441-1810.1128/JVI.01441-1830282713 17.KimM.KimS.Y.LeeH.W.ShinJ.S.KimP.JungY.S.JeongH.S.HyunJ.K.LeeC.K.Inhibition of influenza virus"/>
 <result pre="Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix" exact="Protein" post="2 FunctionJ. Virol.201892e01441-1810.1128/JVI.01441-1830282713 17.KimM.KimS.Y.LeeH.W.ShinJ.S.KimP.JungY.S.JeongH.S.HyunJ.K.LeeC.K.Inhibition of influenza virus internalization by"/>
 <result pre="of influenza virus fusion: Structure-activity relationship and interaction with the" exact="viral" post="hemagglutininJ. Virol.2010844277428810.1128/JVI.02325-0920181685 23.KallewaardN.L.CortiD.CollinsP.J.NeuU.McAuliffeJ.M.BenjaminE.Wachter-RosatiL.Palmer-HillF.J.YuanA.Q.WalkerP.A.et al.Structure and Function Analysis of an"/>
 <result pre="viral hemagglutininJ. Virol.2010844277428810.1128/JVI.02325-0920181685 23.KallewaardN.L.CortiD.CollinsP.J.NeuU.McAuliffeJ.M.BenjaminE.Wachter-RosatiL.Palmer-HillF.J.YuanA.Q.WalkerP.A.et al.Structure and Function Analysis of an" exact="Antibody" post="Recognizing All Influenza A SubtypesCell201616659660810.1016/j.cell.2016.05.07327453466 24.YoonH.SongJ.M.RyuC.J.KimY.G.LeeE.K.KangS.KimS.J.An efficient strategy for"/>
 <result pre="downregulate the innate immune response and reduce host resistance to" exact="viral" post="infectionJ. Exp. Med.202021710.1084/jem.20190554 29.MatsuiK.OzawaM.KisoM.YamashitaM.MaekawaT.KubotaM.SuganoS.KawaokaY.Stimulation of alpha2-adrenergic receptors impairs influenza"/>
 <result pre="and yellow, van der Waals. Figure 2 Inhibition of influenza" exact="virus infection" post="by nylidrin. (A) Western blot analysis showing the dose-dependent"/>
 <result pre="yellow, van der Waals. Figure 2 Inhibition of influenza virus" exact="infection" post="by nylidrin. (A) Western blot analysis showing the dose-dependent"/>
 <result pre="nylidrin. (A) Western blot analysis showing the dose-dependent decrease in" exact="viral" post="proteins by nylidrin. Madin-Darby canine kidney (MDCK) cells were"/>
 <result pre="24 h with the PR8 virus at a multiplicity of" exact="infection" post="(MOI) of 0.001 in the presence of dimethyl sulfoxide"/>
 <result pre="carboxylate (OSV-C; 10 μM), or ribavirin (RBV; 100 μM). Each" exact="viral" post="protein and α-actin, as a loading control, are marked"/>
 <result pre="the right side of the gels. (B) Plaque reduction assay." exact="Viral" post="titers were determined using culture supernatants from the same"/>
 <result pre="the presence of DMSO (delivery vehicle) or nylidrin (100 μM)." exact="Viral" post="NP (green) and cellular nuclei (blue) were detected using"/>
 <result pre="fixed and permeabilized for probing anti-NP antibody and Alexa 633-conjugated" exact="secondary" post="antibody. Mock, no PR8 infection. Green, an EGFP-tagged endosomal"/>
 <result pre="an EGFP-tagged endosomal marker, Rab5 (upper) or Rab7 (lower). Red," exact="viral" post="NP. Blue, cellular nuclei stained with DAPI. Original magnification,"/>
 <result pre="1 h and subjected to western blot analysis to detect" exact="viral" post="HA1 and HA2 proteins. Uncleaved proteins by trypsin are"/>
 <result pre="nylidrin against a mouse-adapted influenza A virus (H1N1), maPR8. Before" exact="viral" post="challenge, maPR8 (5 MLD50) was preincubated with DMSO (virus"/>
 <result pre="was orally administered twice a day beginning 4 h before" exact="virus infection" post="at 8-h intervals from days 0 to 5 post-infection."/>
 <result pre="orally administered twice a day beginning 4 h before virus" exact="infection" post="at 8-h intervals from days 0 to 5 post-infection."/>
</results>
